Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK comparability of MYL-1402O vs Avastin in healthy volunteers
NCT02469987Phase 1Completed
- Sponsor
- Mylan
- Start
- Apr 2015
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MYL-1402O in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), glioblastoma (GBM) and 4 more (3 arms), sponsored by Mylan. Primary endpoint: Area under the plasma concentration versus time curve (AUC0-inf) at 2352 hours. Started Apr 2015; status: completed.
02
Drugs
MYL-1402O
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)glioblastoma (GBM)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02469987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469987.